A clinical research on the amount of liver fat when treated with the combination therapy of interferon and DFPP (Double filtration plasmapheresis) measured by MRS(Magenetic Resonance Spectroscopy)

A clinical research on the amount of liver fat when treated with the combination therapy of interferon and DFPP (Double filtration plasmapheresis) measured by MRS(Magenetic Resonance Spectroscopy) - Clinical research on the amount of liver fat when treated with the combination therapy of interferon and DFPP.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002415

Enrollment

Registered

2010-01-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

combined with DFPP combined without DFPP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed chronic hepatitis C patients. Patients whose written informed consents are obtained.

Exclusion criteria

Exclusion criteria: 1) Patients ever experienced shock during extracorporeal therapy. 2) Patients who has previous history of hypersensitivity for biological pruducts such as interferon and vaccines. 3) Patients who are now being administered shoo-saikoto. 4) Patients with autoimmune hepatitis. 5) Patients ever experienced a hyper-sensitivity against nucleoside analogues( aciclovir, ganciclovir, vidarabine etc). 6) Patients with uncontrollable cardiac disorder( myocardial infarction, heart failure, arrhythmia) . 7) Patients with hemoglobinopathy (thalassemia, drepanocytic anemia). 8) Patients with chronic renal failure, or whose creatine clearances are under 50mL/min. 9) Patients with serious depression, serious mental state such as suicidal ideation, suicide attempt, or with those histories. 10) Patients with severe hepatic dysfunction. 11) Patients whose platelet numbers are less than 50,000/&#61549;L upon registration or before the first DFPP. 12) Patients whose fibrinogen levels are less than 100mg/dL upon registration or before the first DFPP. 13) Patients installed or planted with metals( including metal powder) , cardiac pacemaker, implantable nerve stimulator, implantable defibrillator, or cerebrospinal drain tube. 14) Patients who had participated in other clinical researches or clinical trials. 15) Pregnant women, nursing women, or possible pregnant. 16) Additionally, patients who had been judged as unsuitable for this clinical research by the doctors.

Design outcomes

Primary

Measure	Time frame
Comparison of liver fat before and at the ninth day of DFPP.	—

Secondary

Measure	Time frame
1) Comparison of HCV-RNA before, 4weeks and 12weeks after the initiation of DFPP. 2) Comparison of the amount of liver fat 4weeks and 12weeks after the initiation of DFPP. 3) Comparison of blood triglyceride and serum ferritin before, 4weeks and 12weeks after the initiation of DFPP.	—

Countries

Japan

Contacts

Public ContactTatsuya Yamashita

Kanazawa University Hospital Department of Gastrenterology

076-265-2861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026